Eliska Svastova

Dr. Eliska Svastova

Biomedical Research Center, Institute of Virology, Slovak Academy of Sciences, Bratislava, Slovakia
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2004 in FEBS Letters
Verified
Journal Article
Closed access
Eliska SvastovaEliska Svastova
Eliska Svastova
AHAlžbeta Hulı́ková
Alžbeta Hulı́ková
MRMonika Rafajová
Monika Rafajová
MZMiriam Zat'Ovičová
Miriam Zat'Ovičová
AGAdriana Gibadulinová
Adriana Gibadulinová
SPSilvia Pastoreková
Silvia Pastoreková

1 November 2003 in Experimental Cell Research
Verified
Journal Article
Closed access
Eliska SvastovaEliska Svastova
Eliska Svastova
NŽNorbert Žilka
Norbert Žilka
MZMiriam Zat'OVičová
Miriam Zat'OVičová
AGAdriana Gibadulinová
Adriana Gibadulinová
FČFedor Čiampor
Fedor Čiampor
SPSilvia Pastoreková
Silvia Pastoreková

1 January 2014 in Frontiers in Physiology
Verified
Journal Article
Open access
PDF file
OSOlga Sedlakova
Olga Sedlakova
Eliska SvastovaEliska Svastova
Eliska Svastova
MTMartina Takacova
Martina Takacova
JKJuraj Kopacek
Juraj Kopacek
JPJaromir Pastorek
Jaromir Pastorek
SPSilvia Pastorekova
Silvia Pastorekova
Acidic tissue microenvironment contributes to tumor progression via multiple effects including the activation of angiogenic factors and proteases, reduced cell-cell adhesion, increased migration and invasion, etc. In addition, intratumoral acidosis can influence the uptake of anticancer drugs and modulate the response of tumors to conventional therapy. Acidification of the tumor microenvironment often develops due to hypoxia-triggered oncogenic metabolism, which leads to the extensive production of lactate, protons and carbon dioxide. In order to avoid intracellular accumulation of the acidic metabolic products, which is incompatible with the survival and proliferation, tumor cells activate molecular machinery that regulates pH by driving transmembrane inside-out and outside-in ion fluxes. Carbonic anhydrase IX (CA IX) is a hypoxia-induced catalytic component of the bicarbonate import arm of this machinery. Through its catalytic activity, CA IX directly participates in many acidosis-induced features of tumor phenotype as demonstrated by manipulating its expression and/or by in vitro mutagenesis. CA IX can function as a survival factor protecting tumor cells from hypoxia and acidosis, as a pro-migratory factor facilitating cell movement and invasion, as a signaling molecule transducing extracellular signals to intracellular pathways (including major signaling and metabolic cascades) and converting intracellular signals to extracellular effects on adhesion, proteolysis and other processes. These functional implications of CA IX in cancer are supported by numerous clinical studies demonstrating the association of CA IX with various clinical correlates and markers of aggressive tumor behavior. Although our understanding of the many faces of CA IX is still incomplete, existing knowledge supports the view that CA IX is a biologically and clinically relevant molecule, exploitable in anticancer strategies aimed at targeting adaptive responses to hypoxia and/or acidosis.

1 January 2012 in Journal of Biological Chemistry
Verified
Journal Article
Open access
Eliska SvastovaEliska Svastova
Eliska Svastova
WWwojciech witarski
wojciech witarski
LCLucia Csaderova
Lucia Csaderova
IKIvan Kosik
Ivan Kosik
LSLucia Skvarkova
Lucia Skvarkova
SPSilvia Pastorekova
Silvia Pastorekova
Carbonic anhydrase IX (CA IX) is a hypoxia-induced cell surface enzyme expressed in solid tumors, and functionally involved in acidification of extracellular pH and destabilization of intercellular contacts. Since both extracellular acidosis and reduced cell adhesion facilitate invasion and metastasis, we investigated the role of CA IX in cell migration, which promotes the metastatic cascade. As demonstrated here, ectopically expressed CA IX increases scattering, wound healing and transwell migration of MDCK cells, while an inactive CA IX variant lacking the catalytic domain (ΔCA) fails to do so. Correspondingly, hypoxic HeLa cells exhibit diminished migration upon inactivation of the endogenous CA IX either by forced expression of the dominant-negative ΔCA variant or by treatment with CA inhibitor, implying that the catalytic activity is indispensable for the CA IX function. Interestingly, CA IX improves cell migration both in the absence and presence of hepatocyte growth factor (HGF), an established inducer of epithelial-mesenchymal transition. On the other hand, HGF up-regulates CA IX transcription and triggers CA IX protein accumulation at the leading edge of lamellipodia. In these membrane regions CA IX co-localizes with sodium bicarbonate co-transporter (NBCe1) and anion exchanger 2 (AE2) that are both components of the migration apparatus and form bicarbonate transport metabolon with CA IX. Moreover, CA IX physically interacts with AE2 and NBCe1 in situ, as shown here for the first time. Thus, our findings suggest that CA IX actively contributes to cell migration via its ability to facilitate ion transport and pH control at protruding fronts of moving cells.

15 December 2011 in Cancer Research
Verified
Journal Article
Closed access
PDF file
PDPeter Ditte
Peter Ditte
FDFranck Dequiedt
Franck Dequiedt
Eliska SvastovaEliska Svastova
Eliska Svastova
AHAlzbeta Hulikova
Alzbeta Hulikova
AOAnna Ohradanova-Repic
Anna Ohradanova-Repic
JPJaromir Pastorek
Jaromir Pastorek
In the hypoxic regions of a tumor, carbonic anhydrase IX (CA IX) is an important transmembrane component of the pH regulatory machinery that participates in bicarbonate transport. Because tumor pH has implications for growth, invasion, and therapy, determining the basis for the contributions of CA IX to the hypoxic tumor microenvironment could lead to new fundamental and practical insights. Here, we report that Thr443 phosphorylation at the intracellular domain of CA IX by protein kinase A (PKA) is critical for its activation in hypoxic cells, with the fullest activity of CA IX also requiring dephosphorylation of Ser448. PKA is activated by cAMP, which is elevated by hypoxia, and we found that attenuating PKA in cells disrupted CA IX-mediated extracellular acidification. Moreover, following hypoxia induction, CA IX colocalized with the sodium-bicarbonate cotransporter and other PKA substrates in the leading edge membranes of migrating tumor cells, in support of the concept that bicarbonate metabolism is spatially regulated at cell surface sites with high local ion transport and pH control. Using chimeric CA IX proteins containing heterologous catalytic domains derived from related CA enzymes, we showed that CA IX activity was modulated chiefly by the intracellular domain where Thr443 is located. Our findings indicate that CA IX is a pivotal mediator of the hypoxia-cAMP–PKA axis, which regulates pH in the hypoxic tumor microenvironment. Cancer Res; 71(24); 7558–67. ©2011 AACR.

8 November 2005 in British Journal of Cancer
Verified
Journal Article
Open access
MZM Zatovicova
M Zatovicova
OSO Sedlakova
O Sedlakova
Eliska SvastovaEliska Svastova
Eliska Svastova
AOAnna Ohradanova-Repic
Anna Ohradanova-Repic
FCF Ciampor
F Ciampor
SPSilvia Pastorekova
Silvia Pastorekova
Carbonic anhydrase IX (CA IX) is a transmembrane protein whose expression is strongly induced by hypoxia in a broad spectrum of human tumours. It is a highly active enzyme functionally involved in both pH control and cell adhesion. Its presence in tumours usually indicates poor prognosis. Ectodomain of CA IX is detectable in the culture medium and body fluids of cancer patients, but the mechanism of its shedding has not been thoroughly investigated. Here, we analysed several cell lines with natural and ectopic expression of CA IX to show that its ectodomain release is sensitive to metalloprotease inhibitor batimastat (BB-94) and that hypoxia maintains the normal rate of basal shedding, thus leading to concomitant increase in cell-associated and extracellular CA IX levels. Using CHO-M2 cells defective in shedding, we demonstrated that the basal CA IX ectodomain release does not require a functional TNFα-converting enzyme (TACE/ADAM17), whereas the activation of CA IX shedding by both phorbol-12-myristate-13-acetate and pervanadate is TACE-dependent. Our results suggest that the cleavage of CA IX ectodomain is a regulated process that responds to physiological factors and signal transduction stimuli and may therefore contribute to adaptive changes in the protein composition of tumour cells and their microenvironment.